The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus

Publication date: April 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 2Author(s): Martin H. Strauss, Alistair S. HallAbstractThe renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's also reduce the risk for myocardial infarction (MI) and all-cause mortality in high-risk hypertensive patients as well as in people with diabetes, vascular disease and congestive heart failure. ARBs, in contrast, do not reduce the risk for MI or death in randomized clinical trials when assessed vs. placebo. Systematic reviews of ARBs that include meta-analyses or metaregression analyses confirm that ARBs lack the cardiovascular-protective effects of ACEi's.Practice guidelines, especially those for high-risk patients, such as those with diabetes mellitus, should reflect the evidence that ACEi's and ARBs have divergent cardiovascular effects: ACEi's reduce mortality, whereas ARBs do not. ACEi's should remain the preferred RAAS inhibitor for patients at high risk.RésuméLe système rénine-angiotensine-aldostérone (SRAA) joue un r&o...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research

Related Links:

Publication date: Available online 2 June 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Xin Liu, Lin Shi, Xiaoshuang Dai, Huangtao Chen, Chenglin Zhang, Pei Wang, Qian Wu, Lingxia Zeng, Hong Yan
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Bigfoot Biomedical hasn't let the coronavirus pandemic stand in the way of bringing its injection-based digitized insulin dosing platform to the U.S. market. If anything, CEO Jeffrey Brewer says the pandemic has "only crystalized the need for medical solutions like ours that facilitate remote care, remote support, and home delivery." The company has raised a total of $55 million to close its series C equity financing. Abbott led the round with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management, along with n...
Source: MDDI - Category: Medical Devices Tags: Business R & D Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
CONCLUSION: SHED combined with HBO therapy was effective for treating type 2 diabetic rats. The underlying mechanism may involve SHED-mediated increase in the proliferation and trans-differentiation of islet β -cells and decrease in pro-inflammatory cytokines and apoptosis of islets.
Source: Clinics - Category: General Medicine Source Type: research
Background and aim Recent clinical trials have confirmed that Helicobacter pylori infection is positively associated with nonalcoholic fatty liver disease (NAFLD), although some research has shown a negative association. Therefore, to confirm whether H. pylori eradication treatment is feasible for NAFLD patients in our hospital, we aimed to establish the association between H. pylori infection and NAFLD. Methods We enrolled 91 patients with NAFLD diagnosed by abdominal B-mode ultrasonography between January and December 2018. H. pylori infection was confirmed by C13 urea breath test, and liver function, glycometabolis...
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
Conclusion FIB4A is a potential marker for early detection of NBNC-HCC in patients with diabetes mellitus. However, further studies are needed to confirm these findings.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
The drug hydroxychloroquine that’s been the subject of heated debate as a potential treatment for COVID-19 was not effective in preventing the disease in Canadians and Americans at high risk, according to the first gold standard trial.
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news
Publication date: Available online 22 December 2017 Source:Canadian Journal of Diabetes Author(s): Martin H. Strauss, Alistair S. Hall The renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's also ...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
Abstract PURPOSE: The purpose of this study is to report on the effect of using CHA2DS2VASc (congestive heart failure, hypertension, age ≥75 years [doubled], type 1 or type 2 diabetes mellitus, stroke or transient ischemic attack or thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75 years, sex category [female]) rather than CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke) to determine candidacy for anticoagulant prophylaxis in insured patients with atrial fibrillation (AF). M...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research
More News: Accidents | Canada Health | Cardiology | Cardiovascular | Clinical Trials | Congestive Heart Failure | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Heart Failure | Hypertension | Stroke